Modular Medical: Nine in 10 Surveyed Injection Users Are Open to Simpler Insulin Delivery. Pivot Would Like a Word. -( $MODD )

New Patient Research Strengthens the Case for MODD‘s Pivot

Medical technology often competes by adding features. Modular Medical (NASDAQ:MODD) is pursuing a different proposition: make insulin delivery less demanding for the people who must manage it every day. New patient research announced November 9 gives that strategy a persuasive commercial foundation. In a three-phase study conducted with Thrivable involving more than 540 people with Type 1 or Type 2 diabetes, approximately nine out of 10 surveyed multiple daily injection users said they would consider a simpler insulin delivery option. In the final-phase survey of 303 participants, 48.5% expressed strong interest in the company’s Pivot tubeless patch pump. The distinction matters. General enthusiasm for something easier is not the same as product-specific interest, and neither is a prescription. Still, the findings suggest Modular Medical is addressing a recognizable problem rather than inventing one for the benefit of a presentation deck. For many following MODD, the emerging opportunity centers on one word: simplicity. The company has already moved beyond the purely developmental stage. Its annual report documents U.S. Food and Drug Administration clearance for Pivot in April 2026, followed by commercial availability and initial patient shipments in June. The question now is whether a differentiated product, improving access and more focused patient education can turn that regulatory foundation into a repeatable commercial business.

The Opportunity Is Not Just a Better Pump. It Is a More Approachable Transition.

Modular Medical’s strategy targets people who require intensive insulin therapy but have remained on multiple daily injections, including those discouraged by the perceived cost, complexity or inconvenience of pump therapy. Its SEC filings describe an effort to expand wearable insulin delivery beyond highly motivated users by simplifying the experience from prescription and reimbursement through training and everyday use. Pivot is a wearable, tubeless system designed to provide continuous subcutaneous insulin infusion, including background basal insulin and mealtime bolus dosing, over a three-day wear period. The company positions it as a practical route from injections to pump therapy. That creates a potentially attractive commercial distinction. A business built around helping hesitant patients enter a category need not rely exclusively on persuading satisfied pump users to switch brands. The bullish interpretation is straightforward: reducing the effort required to adopt a technology may be as commercially important as improving the technology itself.

What the Thrivable Study Actually Found

The November research combined an initial phase involving more than 230 participants, 20 in-depth interviews drawn from that cohort, and a final survey of 303 multiple daily injection users. Participants included people considering pumps, former pump users who had returned to injections and people who had adopted pump therapy. Several findings stand out:

• Among respondents classified as highly burdened by their treatment, 82.8% said they would discuss Pivot with a healthcare provider. Even among low-burden respondents, 64.8% expressed that willingness.
• Lower cost, cited by 59.7%, and reduced effort, cited by 57.4%, were the leading factors that could encourage consideration of an alternative insulin delivery method. These are patient priorities, not proof that Pivot has already achieved either advantage in practice.
• Among pump-naïve participants, 41.8% identified the absence of a healthcare provider recommendation as their primary reason for not adopting a pump.
• A practical question topped the educational agenda: 54.1% wanted to know how securely the device remains attached during everyday activities.

That last finding is particularly revealing. Technology companies may prefer to discuss architecture. Patients would also like to know whether the product will remain where they put it. More seriously, the results provide an unusually concrete commercialization agenda: explain everyday use, address affordability, reduce perceived effort and help clinicians identify appropriate candidates. The research should be read as market intelligence rather than clinical validation. It measured self-reported attitudes and reactions to product information, not improvements in glucose control, sustained device use or purchasing behavior. The company itself cautioned that the findings may not represent the broader patient population or predict actual adoption.

Type 2 Diabetes Offers a Particularly Interesting Opening

The Type 2 findings add an important dimension to the story. In the initial research phase, before detailed product messaging, 85.1% of Type 2 respondents expressed strong interest, compared with 53.6% of Type 1 respondents. In the broader survey, favorable perceptions of Pivot were reported by 57.8% of Type 2 respondents and 38.9% of Type 1 respondents. Those are separate measures from different research stages, not interchangeable adoption forecasts. Nevertheless, the direction is encouraging. Within this sample, Type 2 respondents appeared especially receptive to a simpler insulin delivery proposition. The November findings also follow an earlier research initiative announced in July that supported the company’s emphasis on easier-to-learn insulin delivery. The releases should not be treated as independent clinical confirmations or combined into a single statistical sample, but they show continuity in the company’s commercial research priorities. For many evaluating MODD, that consistency matters. The company is not merely describing a device. It is refining a thesis about who might use it and why.

The Commercial Plan Is Becoming More Concrete

Patient interest is valuable. A practical route to reaching those patients is more valuable still. In August, Modular Medical announced plans for an initial commercialization phase beginning in October across five selected U.S. markets: Atlanta, Cincinnati/Lexington, Dallas, Houston and Philadelphia. The company said the approach would concentrate resources in markets with leading insulin pump prescribers and strong new-pump adoption, with commercialization support from Inizio. The announcement established a targeted rollout plan, not evidence that every market has since achieved meaningful sales. Even so, the logic is appealing: concentrate early resources where relevant clinicians and prospective users are accessible, then use operating experience to inform expansion. The company also announced plans to showcase Pivot at the Association of Diabetes Care & Education Specialists annual conference in August. Its stated objectives included engaging diabetes care and education specialists, gathering feedback and securing qualified leads ahead of the planned market rollout. These activities fit the November study’s findings. If a missing provider recommendation is a major barrier, clinician awareness is not a supporting detail. It is part of the sales engine.

A National PBM Agreement Addresses the Affordability Question

The most commercially consequential developments may be the least photogenic. On September 4, Modular Medical announced a contract with a national U.S. pharmacy benefit manager, making Pivot available through that PBM. The company described the agreement as an important step toward broadening patient access. That development connects directly to the research: lower cost was the most frequently cited factor that could encourage consideration of a different insulin delivery method. The agreement does not, by itself, establish universal coverage, a particular patient copayment or a guaranteed volume of prescriptions. The announcement did not identify the PBM or quantify the resulting revenue opportunity. But it does move the discussion toward the mechanics that determine whether interest can become use. A medical device can win admiration in a consultation room and still lose the transaction at the pharmacy counter. For MODD, expanding practical access could prove as important as expanding awareness.

Better Software and Better Education Reinforce the Same Strategy

Modular Medical is also improving the product experience around its central simplicity proposition. On September 3, the company announced FDA clearance for software enhancements that added flexibility and customization in bolus dosing, an enhanced user interface and other upgrades. One cited capability allows users to customize the amount of insulin delivered with each button push. These improvements should not be confused with clearance for a fully automated insulin delivery system. Their immediate relevance is more specific: increasing flexibility while making the existing platform more useful to patients. The educational strategy follows a similar pattern. In October, Modular Medical introduced digital learning resources developed with Relevate Health Games. One module offers an approximately 15-minute virtual walkthrough covering unpacking, preparing, applying and operating Pivot. The company explicitly described the tools as complements to professional training, not replacements for it. Taken together, the software and education initiatives address two different sources of hesitation: how the device works and how difficult it may be to learn. That is a commercially coherent combination. A simpler product benefits from an equally approachable introduction.

Clinical Guidance Adds Structure to the Expansion Effort

The company’s July formation of a Pivot Innovation Council, chaired by Robert Gabbay, MD, PhD, FACP, adds another layer to the commercialization effort. The council’s stated remit includes patient identification, clinical workflow integration and evidence generation. Those responsibilities are relevant to the opportunity suggested by the Thrivable research. Patients may express interest, but clinicians still need to determine suitability, fit the product into practice workflows and evaluate the evidence supporting its use. The council is not proof of commercial success. It is a mechanism intended to help the company address the practical issues that stand between an appealing product proposition and routine clinical adoption. For an early commercial-stage business, those operational details deserve attention. Markets are rarely conquered by enthusiasm alone, however well typeset.

Why MODD’s Simplicity Thesis Deserves Attention

The strongest argument for Modular Medical is not that a patient survey guarantees sales. It is that several parts of the business are beginning to address the same problem from different directions. The company has an FDA-cleared product and initial shipment history. Its research identifies interest in less burdensome insulin delivery. Its planned rollout concentrates commercial resources. A national PBM agreement addresses access, while software updates, digital education and clinical guidance support the transition from injections to pump use. The next meaningful evidence will be commercial: how effectively those elements produce active users, durable demand and a financially supportable expansion. For many watching MODD, the attraction is a business proposition that is refreshingly understandable. Diabetes management already asks a great deal of patients. Modular Medical is building its case around asking a little less.

The Sources

1. Modular Medical: Comprehensive Patient Market Research Study With Thrivable, November 9, 2026
2. SEC.gov: Modular Medical Form 10-K for the Fiscal Year Ended March 31, 2026
3. SEC.gov: Modular Medical Form 10-Q for the Quarter Ended June 30, 2026
4. SEC.gov: Modular Medical Form S-3 Registration Statement
5. Modular Medical: Official Company and Pivot Product Overview
6. Modular Medical: Planned Pivot Launch Across Five Key U.S. Markets, August 3, 2026
7. Modular Medical: National U.S. Pharmacy Benefit Manager Contract, September 4, 2026
8. Modular Medical: FDA Clearance of Pivot Software Enhancements, September 3, 2026
9. Modular Medical: Digital Learning Tools to Support Pivot Adoption, October 15, 2026
10. Modular Medical: Formation of Pivot Innovation Council and Appointment of Robert Gabbay as Chairman, July 23, 2026
11. Modular Medical: Research Initiative on Interest in Simpler Insulin Delivery, July 14, 2026
12. Modular Medical: Participation in the Association of Diabetes Care & Education Specialists Annual Conference, August 5, 2026